Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis
Dose-Response · 2026-04 · 24 (2)
DOI: 10.1177/15593258261449239 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Dose-Response, online erschienen am 05.05.2026. Verfasst von Omar Abdullah Gill und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, King Edward Medical University, Lahore, Pakistan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Lorundrostat, an aldosterone synthase inhibitor, shows promise for hypertension management, though optimal dosing strategies remain poorly defined.
Aims
To evaluate the efficacy, safety, and dose-response effects of Lorundrostat to identify the optimal therapeutic dose.
Methods
We searched PubMed, Embase, Scopus, and ClinicalTrials.gov systematically for relevant RCTs. Using a random-effects model, data were pooled to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CIs). Dose-response modeling was performed using “dosresmeta” and “rcs” packages in R (v4.4.3).
Results
Three RCTs (n=1568) were included. Lorundrostat significantly reduced systolic BP at 4–8 weeks (MD: –7.66 mmHg, 95% CI: –10.42 to –4.89) and 12 weeks (MD: –10.19 mmHg, 95% CI: –13.57 to –6.82). Diastolic BP also decreased significantly (MD: –3.81). Sub-group analysis based on background medication count showed no significant differences (P=0.80). Aldosterone levels were significantly reduced (MD: –4.39). Dose-response modeling identified 60 mg as the optimal dose, with diminishing returns thereafter. While hyperkalemia risk increased (RR: 3.19), no significant differences were found in serious adverse events.
Conclusion
Lorundrostat effectively lowers BP with a manageable safety profile. The modeling-based insights suggest 60 mg as the optimal dose, delineating a clearer therapeutic window.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, King Edward Medical University, Lahore, Pakistan.
- Autonomous University of the State of Morelos, México.
- Poonch Medical College, Rawalakot, Pakistan.
- Dow University of Health Science, Karachi, Pakistan.
- Dayanand Medical College and Hospital, Ludhiana, India.
- Rajiv Gandhi Centre for Diabetes and Endocrinology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India.
ORCID-Profile: Dori Woldu
Zitieren
APA
Gill, O. A., Monterrubio, M. L. S., Rashid, A., Habib, E., Yasin, A., Alam, A., Khan, A., Tahir, R., Bansal, S., Benny, O., Sabarish, S., Arvapalli, L. S., Bhanderi, D., Layi, S. I., Haris, H. M., & Woldu, D. (2026). Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis. Dose-Response, 24(2). https://doi.org/10.1177/15593258261449239
Vancouver
Gill OA, Monterrubio MLS, Rashid A, Habib E, Yasin A, Alam A, et al. Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis. Dose-Response. 2026;24(2). doi:10.1177/15593258261449239
BibTeX
@article{Gill2026,
author = {Gill, Omar Abdullah and Monterrubio, Miguel Leonardo Salcedo and Rashid, Ayeman and Habib, Erum and Yasin, Asma and Alam, Ahmad and Khan, Azhar and Tahir, Ramesha and Bansal, Savika and Benny, Olivia and Sabarish, Shivani and Arvapalli, Lakshmi Sheethal and Bhanderi, Devanshi and Layi, Salau Ibrahim and Haris, Hafiz Muhammad and Woldu, Dori},
title = {Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis},
journal = {Dose-Response},
year = {2026},
volume = {24},
number = {2},
doi = {10.1177/15593258261449239}
}
EUVIMED